Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Violations Trigger Bans On 73 Drug Advertisements

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has released a report on illegal pharmaceutical, medical device and health food advertisements identified during the June to December period of 2008. This report is a compilation of reports sent from local food and drug administrative bodies that covered 24,565 illegal pharmaceutical advertisements, 1,532 illegal medical device advertisements and 15,196 illegal health food advertisements. Ten provinces, including Jilin, Shanxi, and Qinghai, have revoked licenses for a total of 73 advertisements due to their obvious digression from previously approved content. These illegal, highly visible advertisements claimed or guaranteed product results without scientific evidence. In addition, some illegal pharmaceutical or medical device ads seriously deceived or mislead consumers by using patients or medical institutions for product testimony. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel